Strategic Focus Clinical-stage biotechnology company focused on allergy and IgE/IgG4 antibody technologies, presenting opportunities to partner on late-stage discovery, translational research, and potential IgG4-based therapeutics for allergic diseases.

Recent Excitement Active pursuit and public announcements around Alpha-gal Syndrome monoclonal antibody discovery and forthcoming presentations, signaling readiness for collaborations, licensing discussions, and sponsored research with pharma and biotech partners.

Funding & Growth Well-funded with substantial Series B backing and venture syndicate, indicating capacity for joint development programs, milestone-driven partnerships, and shared risk models suitable for co-development and out-licensing deals.

Target Markets Focus on allergic diseases with innovative monoclonal IgG4 strategies, offering a foothold in a scalable niche with potential entry points in peanut allergy and related IgE-driven conditions, ideal for partner-backed clinical development programs.

Operational Advantage Small but high-potential team based in South San Francisco with strong academic origins, suggesting agility for rapid collaboration, tight IP protection, and a preference for strategic alliances with larger pharmaceutical players.